Biohaven Pharma (BHVN) Tops Q2 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $98 at Wedbush, After Financing Agreement Announcement
August 7, 2020 1:36 PM EDTWedbush analyst Laura Chico raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $98.00 (from $94.00) while maintaining a Outperform rating.
... MoreBiohaven Pharma (BHVN) Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street
August 7, 2020 9:52 AM EDTBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced that it entered into a $500 million non-dilutive term loan financing facility with Sixth Street, a leading global investment firm.
The Sixth Street term loan facility will be available to Biohaven under the following terms:
Up to $500M in a structured term loan facility. Biohaven will use the proceeds for the development, promotion, and commercial launch of NURTEC ODT, as well as for... MoreBiohaven Pharma (BHVN), Royalty Pharma (RPRX) Announce Funding Agreement Totaling up to $450 Million
August 7, 2020 9:38 AM EDTBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Royalty Pharma (Nasdaq: RPRX) announced today that Biohaven has secured up to $250 million in funding to advance the company's CGRP receptor antagonist program through the development of zavegepant (formerly known as vazegepant). The zavegepant program encompasses intranasal zavegepant as well as oral zavegepant for migraine prevention and non-migraine indications. In exchange for these funds, Royalty Pharma will obtain a 0.4% royalty on annual worldwide net sales of Nurtec® ODT and if certain zavegepant regulatory approvals are achieved, a royalty of up to 3% on... More
